Corbus Pharma (CRBP) Receives EC Orphan Designation for Resunab as CF Treatment

Corbus Pharma (CRBP) Receives EC Orphan Designation for Resunab as CF Treatment

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) announced that the European Commission has granted Orphan Designation in the European Union for the Company’s novel synthetic oral endocannabinoid-mimetic drug, Resunab, for the treatment of cystic fibrosis (“CF”). Read more >>

Share this post